ProPhase Labs, Inc.

Equities

PRPH

US74345W1080

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
4.71 USD -4.85% Intraday chart for ProPhase Labs, Inc. -10.46% +4.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Ticks Up After UnitedHealth Earnings -- Health Care Roundup DJ
ProPhase Labs, Inc. Unveils Project ZenQ-AI CI
Transcript : ProPhase Labs, Inc., 2023 Earnings Call, Mar 15, 2024
ProPhase Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Inflation -2- DJ
Prophase Labs, Inc. Announces Important Developments in the Company?s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test CI
ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir CI
ProPhase Labs Names Jed Latkin as Chief Operating Officer MT
ProPhase Labs, Inc. Appoints Jed Latkin as COO CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on March 15, 2023. CI
HC Wainwright Cuts Price Target on ProPhase Labs to $11 From $14, Maintains Buy Rating MT
Transcript : ProPhase Labs, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (PRPH) PROPHASE LABS Posts Q3 Revenue $8.4M MT
ProPhase Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ProPhase Labs, Inc.'s Equity Buyback announced on March 15, 2023, has expired with 69,628 shares, representing 0.43% for $0.59 million. CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on March 15, 2023. CI
Transcript : ProPhase Labs, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (PRPH) PROPHASE LABS Reports Q2 Revenue $13.2M MT
ProPhase Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Navidea Biopharmaceuticals Confirms Rejection of ProPhase Labs' Proposal to Buy Some of Its Assets MT
ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected MT
ProPhase Labs, Inc. cancelled the acquisition of Certain Assets from Navidea Biopharmaceuticals, Inc. for $7 million. CI
ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1 CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on July 26, 2022. CI
Tranche Update on ProPhase Labs, Inc.'s Equity Buyback Plan announced on March 15, 2023. CI
Chart ProPhase Labs, Inc.
More charts
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. PRPH Stock
  4. News ProPhase Labs, Inc.
  5. ProPhase Labs Says Offer to Acquire Certain Navidea Biopharmaceuticals' Assets Rejected